A UK domiciled startup is revolutionising the direct to consumer (DTC) healthcare diagnostics market.
The company has innovated a delivery mechanism that allows conditions to be diagnosed immediately in the comfort and convenience of home. The company enables an individual to take ownership of their health, making laboratory level information accessible and painless and thus enfranchising the individual and ultimately democratising healthcare.
The company’s innovation is a diagnostic urinalysis (urine test) kit embedded into a postcard. The postcard and affiliated mobile app, are not only a reliable and non-invasive alternative to costly and time consuming doctor visits but crucially, serve as an early diagnosis tool that prompts earlier medical intervention and treatment. The following conditions can be diagnosed using this unique product:-
* Pregnancy Testing
* Ovulation Optimisation
* Urinary Tract Infection
* Sexually Transmitted Diseases (STIs)
The urinalysis market is expected to reach $1.91 billion by 2021 from $1.32 billion in 2016, at a compounded annual growth rate of 7.6%. The company is on course to disrupt the global diagnostics market with the launch of its application in October and is now undertaking a seed funding round.
The company is looking to raise £150,000 in SEIS seed funding.